RLYB NASDAQ
Rallybio Corporation
1W: +2.8%
1M: +0.8%
3M: +8.7%
YTD: +201.8%
1Y: +3191.6%
3Y: +385.2%
5Y: +22.9%
$17.08
+0.32 (+1.91%)
Weekly Expected Move ±3.9%
$16
$16
$17
$18
$18
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
8 relationships8
As Filer
counterparties named
0
As Counterparty
mentioned by others
4
Rel. Types
2022-05-10
Earliest Filing
2026-03-02
Latest Filing
partner: 4
target: 2
acquirer: 1
investor: 1
Counterparties (Filed by RLYB)
8 relationshipsCompanies named in RLYB's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Candid Therapeutics, Inc. | — | target | Target company in the merger agreement with Rallybio Corporation. | 2026-03-02 | View |
| Farmington Merger Sub, Inc. | — | partner | Wholly-owned subsidiary of Rallybio Corporation acting as the merger subsidiary. | 2026-03-02 | View |
| Recursion Pharmaceuticals, Inc. | RXRX | partner | Counterparty in a Membership Interest Purchase Agreement referenced in the CVR Agreement. | 2026-03-02 | View |
| Exscientia Ventures I, Inc. | — | partner | Counterparty in a Membership Interest Purchase Agreement referenced in the CVR Agreement. | 2026-03-02 | View |
| Recursion Pharmaceuticals, Inc. | RXRX | acquirer | Acquired 50% of ENPP1 JV membership interests from Rallybio in exchange for cash and Class A Common Stock | 2025-07-08 | View |
| Exscientia Ventures I, Inc. | — | investor | Indirect wholly-owned subsidiary of Recursion that participated as Buyer in the purchase of ENPP1 JV membership interest | 2025-07-08 | View |
| Rallybio IPB, LLC | RLYB | target | Wholly-owned subsidiary of Rallybio that sold 50% of ENPP1 JV membership interests to Recursion | 2025-07-08 | View |
| Sanofi | SNYNF | partner | Rallybio entered into a License Agreement to acquire worldwide exclusive rights to Sanofi's KY1066 (RLYB331) for the tre | 2022-05-10 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-09 | Officer/Director Change; Exhibits | View | |
| 2026-06-01 | Material Agreement; Unregistered Equity Sales; Change in Control; Officer/Director Change; Regulatio | Agreement | View |
| 2026-05-04 | Termination of Agreement; Exhibits | View | |
| 2026-03-31 | Officer/Director Change | View | |
| 2026-03-02 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Changes in Contro | Agreement | View |
| 2026-01-29 | Amendments to Articles of Incorporation or Bylaws; Submission of Matters to a Vote of Security Holde | View | |
| 2025-11-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-08-29 | Notice of Delisting or Transfer; Financial Statements and Exhibits | View | |
| 2025-08-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-07-08 | Entry into Material Definitive Agreement; Completion of Acquisition or Disposition of Assets; Other | Agreement Acquisition | View |
| 2025-06-27 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2025-05-16 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-08 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-04-08 | Other Events; Financial Statements and Exhibits | View | |
| 2025-03-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-03-13 | Other Events; Financial Statements and Exhibits | View | |
| 2025-02-25 | Notice of Delisting or Transfer | View | |
| 2024-11-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-09-17 | Departure/Election of Directors; Appointment of Officers | View | |
| 2024-08-08 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR